Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2021; 27(28): 4697-4709
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4697
New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
Xiang-Lei Yuan, Lian-Song Ye, Xian-Hui Zeng, Qing-Hua Tan, Yi Mou, Wei Liu, Chun-Cheng Wu, Hang Yang, Bing Hu
Xiang-Lei Yuan, Lian-Song Ye, Xian-Hui Zeng, Qing-Hua Tan, Yi Mou, Wei Liu, Chun-Cheng Wu, Hang Yang, Bing Hu, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Hu B, Yuan XL, and Ye LS designed this study; Yuan XL, Ye LS, and Zeng XH analyzed and interpreted the data; Yuan XL, Ye LS, and Zeng XH drafted the manuscript; Hu B, Tan QH, Mou Y, Liu W, Wu CC, and Yang H critically revised the manuscript.
Institutional review board statement: The study protocol was approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University.
Informed consent statement: Informed consent was waived by the Ethics Committee because of the retrospective nature of this study and anonymous data.
Conflict-of-interest statement: Prof. Bing Hu is one of the inventors of the antireflux plastic stent. He has worked in collaboration with Micro-Tech (Nanjing) Co. Ltd., Nanjing, China, to develop the stent. No free device was offered for this study. Authors disclosed no conflicts of interests.
Data sharing statement: No additional unpublished data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Hu, MD, Professor, Department of Gastroenterology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubingnj@163.com
Received: May 7, 2021
Peer-review started: May 7, 2021
First decision: June 6, 2021
Revised: June 8, 2021
Accepted: July 7, 2021
Article in press: July 7, 2021
Published online: July 28, 2021
Abstract
BACKGROUND

There is little data available on the role of new anti-reflux plastic stents (ARPSs).

AIM

To compare the use of ARPSs with that of traditional plastic stents (TPSs) for patients with biliary strictures.

METHODS

Consecutive patients with biliary strictures who underwent first endoscopic biliary stenting between February 2016 and May 2019 were included. The onset of stent-related cholangitis, stent patency, clinical success, and other adverse events were evaluated.

RESULTS

Sixty-seven patients in the ARPS group and 66 patients in the TPS group were included in the final analyses. Fewer patients experienced stent-related cholangitis in the ARPS group than that in the TPS group (8 patients vs 18 patients; P = 0.030). The median time till the onset of first stent-related cholangitis was later in the ARPS group than that in the TPS group (128.5 d vs 76 d; P = 0.039). The cumulative median stent patency in the ARPS group was 185 d, which was significantly longer than that in the TPS group (133 d; P = 0.001). The clinical success rates and other adverse events did not significantly differ between both groups.

CONCLUSION

Placement of new ARPS might be a safe and effective optional therapeutic strategy to reduce the risk of stent-related cholangitis and prolong stent patency.

Keywords: Biliary stricture, Plastic stent, Anti-reflux, Endoscopic retrograde cholangiopancreatography

Core Tip: This is a retrospective study to compare the use of new anti-reflux plastic stents (ARPSs) with that of traditional plastic stents (TPSs) for patients with biliary strictures. Fewer patients experienced stent-related cholangitis in the ARPS group than in the TPS group (8 vs 18 patients; P = 0.030). The cumulative median stent patency in the ARPS group was 185 d, which was significantly longer than that in the TPS group (133 d).